|
Delayed
NYSE
21:14:00 02/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 26.05 USD | +4.96% |
|
-2.73% | -15.97% |
| 08-14 | Oppenheimer Adjusts Pelthos Therapeutics PT to $64 From $66, Maintains Outperform Rating | MT |
| 08-13 | Pelthos Therapeutics Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PELTHOS THERAPEUTICS INC. | Other Pharmaceuticals | +4.96% | -2.73% | -15.97% | +15.98% | - | 95.02M |  |  | |
- Stock Market
- Stocks
- PTHS Stock
- Charts Pelthos Therapeutics Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
